5,5-二甲基-2-苯基-吗啉 | 42013-48-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 中文名称: 5,5-二甲基-2-苯基-吗啉
• 英文名称: 2-Phenyl-5,5-dimethyltetrahydro-1,4-oxazin
• 英文别名: 5,5-dimethyl-2-phenyl-morpholine；5,5-Dimethyl-2-phenylmorpholine
• CAS: 42013-48-9
• 化学式: C₁₂H₁₇NO
• mdl: MFCD01713893
• 分子量: 191.273
• InChiKey: KJUOROGOOZJYAI-UHFFFAOYSA-N

物化性质

• 沸点：
  327.03°C (rough estimate)
• 密度：
  1.0096 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  5,5-二甲基-2-苯基-吗啉 、 富马酸 生成 (E)-but-2-enedioic acid;5,5-dimethyl-2-phenylmorpholine
  参考文献：
  名称：

  LAFON, L.

  摘要：

  DOI：
• 作为产物：
  描述：

  2-(2-羟基-2-苯基乙基氨基)-2-甲基丙烷-1-醇 生成 5,5-二甲基-2-苯基-吗啉
  参考文献：
  名称：

  LAFON, L.

  摘要：

  DOI：

文献信息

• COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES
  申请人：Johansen Lisa M.

  公开号：US20100009970A1

  公开（公告）日：2010-01-14

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

  本发明涉及用于治疗病毒性疾病的组合物、方法和试剂盒。在某些实施方式中，病毒性疾病是由单链RNA病毒、黄病毒科病毒或肝病毒引起的。在特定实施方式中，病毒性疾病是病毒性肝炎（例如甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎），药剂或药剂组合包括舍曲林、舍曲林类似物、UK-416244或UK-416244类似物。还包括用于鉴定可用于治疗病毒性疾病的新化合物的筛选方法。
• Morpholine derivatives, pharmaceutical compositions containing them and processes for their preparation
  申请人：JOHN WYETH & BROTHER LIMITED

  公开号：EP0027695B1

  公开（公告）日：1983-10-12
• Methods to accelerate the isolation of novel cell strains from pluripotent stem cells and cells obtained thereby
  申请人：West D. Michael

  公开号：US20080070303A1

  公开（公告）日：2008-03-20

  This invention generally relates to methods to differentiate pluripotent stem cells, such as embryonic stem, embryonic germ, or embryo-derived cells, to obtain subpopulations of cells from heterogeneous mixtures of cells wherein the subpopulation of cells possess reduced differentiation potential compared to the original pluripotent stem cells and where the subpopulation is capable of being propagated.
• Compositions and methods for treatment of viral diseases
  申请人：Johansen Lisa M.

  公开号：US20080161324A1

  公开（公告）日：2008-07-03

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E). Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.
• METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY
  申请人：Advanced Cell Technology, Inc.

  公开号：US20160369237A1

  公开（公告）日：2016-12-22

  This invention generally relates to methods to differentiate pluripotent stem cells, such as embryonic stem, embryonic germ, or embryo-derived cells, to obtain subpopulations of cells from heterogeneous mixtures of cells wherein the subpopulation of cells possess reduced differentiation potential compared to the original pluripotent stem cells and where the subpopulation is capable of being propagated.